Venrock Adviser, LLC
CIK 0001615982 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$3.30B
2026 Q2
Positions
33
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
80.4%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
03770N101
APOGEE THERAPEUTICS INC
34.2%
ORKA
ORUKA THERAPEUTICS INC
12.0%
ERAS
ERASCA INC
9.9%
SYRE
SPYRE THERAPEUTICS INC
8.0%
DNTH
DIANTHUS THERAPEUTICS INC
3.5%
OCUL
OCULAR THERAPEUTIX INC
3.1%
36322Q206
DAMORA THERAPEUTICS INC
2.8%
SVRA
SAVARA INC
2.8%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.